Market Overview

Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case

Share:
Related INCY
Bank Of America Sees NewLink Genetics As 'Undervalued'
Jim Cramer Gives His Opinion On Tripadvisor And Incyte

In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).

In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”

Incyte Corporation closed on Friday at $24.84.

Latest Ratings for INCY

DateFirmActionFromTo
Sep 2017RBC CapitalInitiates Coverage OnSector Perform
Sep 2017BMO CapitalMaintainsOutperform
Sep 2017Raymond JamesUpgradesMarket PerformOutperform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (INCY)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...